Advanced

Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study

Figueiredo, Jane C.; Haile, Robert W.; Bernstein, Leslie; Malone, Kathleen E.; Largent, Joan; Langholz, Bryan; Lynch, Charles F.; Bertelsen, Lisbeth; Capanu, Marinela and Concannon, Patrick, et al. (2010) In Breast Cancer Research and Treatment 120(1). p.175-183
Abstract
The potential effects of oral contraceptive (OC) and postmenopausal hormone (PMH) use are not well understood among BRCA1 or BRCA2 (BRCA1/2) deleterious mutation carriers with a history of breast cancer. We investigated the association between OC and PMH use and risk of contralateral breast cancer (CBC) in the WECARE (Women's Environment, Cancer, and Radiation Epidemiology) Study. The WECARE Study is a population-based case-control study of 705 women with asynchronous CBC and 1,398 women with unilateral breast cancer, including 181 BRCA1/2 mutation carriers. Risk-factor information was assessed by telephone interview. Mutation status was measured using denaturing high-performance liquid chromatography followed by direct sequencing in all... (More)
The potential effects of oral contraceptive (OC) and postmenopausal hormone (PMH) use are not well understood among BRCA1 or BRCA2 (BRCA1/2) deleterious mutation carriers with a history of breast cancer. We investigated the association between OC and PMH use and risk of contralateral breast cancer (CBC) in the WECARE (Women's Environment, Cancer, and Radiation Epidemiology) Study. The WECARE Study is a population-based case-control study of 705 women with asynchronous CBC and 1,398 women with unilateral breast cancer, including 181 BRCA1/2 mutation carriers. Risk-factor information was assessed by telephone interview. Mutation status was measured using denaturing high-performance liquid chromatography followed by direct sequencing in all participants. Outcomes, treatment, and tumor characteristics were abstracted from medical records. Ever use of OCs was not associated with risk among noncarriers (RR = 0.87; 95% CI = 0.66-1.15) or BRCA2 carriers (RR = 0.82; 95% CI = 0.21-3.13). BRCA1 carriers who used OCs had a nonsignificant greater risk than nonusers (RR = 2.38; 95% CI = 0.72-7.83). Total duration of OC use and at least 5 years of use before age 30 were associated with a nonsignificant increased risk among mutation carriers but not among noncarriers. Few women had ever used PMH and we found no significant associations between lifetime use and CBC risk among carriers and noncarriers. In conclusion, the association between OC/PMH use and risk of CBC does not differ significantly between carriers and noncarriers; however, because carriers have a higher baseline risk of second primaries, even a potential small increase in risk as a result of OC use may be clinically relevant. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
BRCA2, BRCA1, Postmenopausal hormones, contraceptives, Oral, Contralateral, Breast cancer, Asynchronous bilateral
in
Breast Cancer Research and Treatment
volume
120
issue
1
pages
175 - 183
publisher
Springer
external identifiers
  • wos:000273743500020
  • scopus:74849126231
ISSN
1573-7217
DOI
10.1007/s10549-009-0455-5
language
English
LU publication?
yes
id
65a9eda1-b2ae-4be0-8e05-d34f06cb0cca (old id 1547343)
date added to LUP
2010-02-24 09:45:17
date last changed
2018-05-29 11:00:41
@article{65a9eda1-b2ae-4be0-8e05-d34f06cb0cca,
  abstract     = {The potential effects of oral contraceptive (OC) and postmenopausal hormone (PMH) use are not well understood among BRCA1 or BRCA2 (BRCA1/2) deleterious mutation carriers with a history of breast cancer. We investigated the association between OC and PMH use and risk of contralateral breast cancer (CBC) in the WECARE (Women's Environment, Cancer, and Radiation Epidemiology) Study. The WECARE Study is a population-based case-control study of 705 women with asynchronous CBC and 1,398 women with unilateral breast cancer, including 181 BRCA1/2 mutation carriers. Risk-factor information was assessed by telephone interview. Mutation status was measured using denaturing high-performance liquid chromatography followed by direct sequencing in all participants. Outcomes, treatment, and tumor characteristics were abstracted from medical records. Ever use of OCs was not associated with risk among noncarriers (RR = 0.87; 95% CI = 0.66-1.15) or BRCA2 carriers (RR = 0.82; 95% CI = 0.21-3.13). BRCA1 carriers who used OCs had a nonsignificant greater risk than nonusers (RR = 2.38; 95% CI = 0.72-7.83). Total duration of OC use and at least 5 years of use before age 30 were associated with a nonsignificant increased risk among mutation carriers but not among noncarriers. Few women had ever used PMH and we found no significant associations between lifetime use and CBC risk among carriers and noncarriers. In conclusion, the association between OC/PMH use and risk of CBC does not differ significantly between carriers and noncarriers; however, because carriers have a higher baseline risk of second primaries, even a potential small increase in risk as a result of OC use may be clinically relevant.},
  author       = {Figueiredo, Jane C. and Haile, Robert W. and Bernstein, Leslie and Malone, Kathleen E. and Largent, Joan and Langholz, Bryan and Lynch, Charles F. and Bertelsen, Lisbeth and Capanu, Marinela and Concannon, Patrick and Borg, Åke and Borresen-Dale, Anne-Lise and Diep, Anh and Teraoka, Sharon and Törngren, Therese and Xue, Shanyan and Bernstein, Jonine L.},
  issn         = {1573-7217},
  keyword      = {BRCA2,BRCA1,Postmenopausal hormones,contraceptives,Oral,Contralateral,Breast cancer,Asynchronous bilateral},
  language     = {eng},
  number       = {1},
  pages        = {175--183},
  publisher    = {Springer},
  series       = {Breast Cancer Research and Treatment},
  title        = {Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study},
  url          = {http://dx.doi.org/10.1007/s10549-009-0455-5},
  volume       = {120},
  year         = {2010},
}